S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Price, News & Analysis

$2.54
+0.29 (+12.89%)
(As of 02/28/2024 ET)
Today's Range
$2.17
$2.74
50-Day Range
$1.41
$2.54
52-Week Range
$1.04
$2.74
Volume
6.83 million shs
Average Volume
738,577 shs
Market Capitalization
$170.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.73

CytomX Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
7.5% Upside
$2.73 Price Target
Short Interest
Healthy
1.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
0.33mentions of CytomX Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$24,327 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $0.01 to ($0.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.25 out of 5 stars

Medical Sector

600th out of 958 stocks

Pharmaceutical Preparations Industry

273rd out of 421 stocks


CTMX stock logo

About CytomX Therapeutics Stock (NASDAQ:CTMX)

CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company's pipeline comprises therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies, and immune modulators, such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditional ADC directed toward CD71. Its clinical pipeline also includes cancer immunotherapeutic candidates against validated targets, such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, as well as CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, it has a preclinical portfolio of wholly owned assets, including CX-801, an interferon alpha-2b Probody cytokine that has potential applicability in immuno-oncology sensitive, as well as insensitive (cold) tumors and CX-2051, an ADC directed toward EpCAM with potential applicability across multiple EpCAM-expressing epithelial cancers. The company has strategic collaborations with various leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. The company was founded in 2008 and is headquartered in South San Francisco, California.

CTMX Stock Price History

CTMX Stock News Headlines

BMY Oct 2024 45.000 put
BMY Apr 2024 52.000 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
BMY Aug 2024 60.000 call
CytomX Therapeutics Inc CTMX
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CytomX Therapeutics Inc (CTMX)
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/29/2024
Next Earnings (Estimated)
3/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTMX
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.73
High Stock Price Target
$3.19
Low Stock Price Target
$2.00
Potential Upside/Downside
+7.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-99,320,000.00
Pretax Margin
-9.74%

Debt

Sales & Book Value

Annual Sales
$53.16 million
Book Value
($1.30) per share

Miscellaneous

Free Float
62,367,000
Market Cap
$170.15 million
Optionable
Optionable
Beta
0.83
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Sean A. McCarthy DPHIL (Age 57)
    Chairman & CEO
    Comp: $1.03M
  • Mr. Lloyd A. Rowland Jr. (Age 67)
    J.D., Senior VP, General Counsel, Chief Compliance Officer & Secretary
    Comp: $608.72k
  • Mr. Jeffrey Landau B.S. (Age 46)
    M.B.A., Senior VP, Head of Strategy & Chief Business Officer
    Comp: $581.68k
  • Mr. Christopher W. Ogden (Age 40)
    Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer
  • Dr. Marcia P. Belvin Ph.D.
    Senior VP & Chief Scientific Officer
  • Dr. Chau Cheng M.B.A.
    Ph.D., Vice President of Investor Relations & Corporate Communications
  • Ms. Danielle Olander-Moghadassian
    Senior VP & Chief Human Resources Officer
  • Ms. Leslie Robbins
    Senior Vice President of Intellectual Property
  • Dr. Yu-Waye Chu M.D. (Age 56)
    Chief Medical Officer
  • Ms. Dawn Benson
    Senior Vice President of Quality & Product Manufacturing














CTMX Stock Analysis - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued twelve-month price objectives for CytomX Therapeutics' shares. Their CTMX share price targets range from $2.00 to $3.19. On average, they predict the company's stock price to reach $2.73 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2024?

CytomX Therapeutics' stock was trading at $1.55 at the beginning of 2024. Since then, CTMX stock has increased by 63.9% and is now trading at $2.54.
View the best growth stocks for 2024 here
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) issued its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biotechnology company had revenue of $17.59 million for the quarter, compared to analysts' expectations of $18.53 million. During the same period in the previous year, the firm earned ($0.32) earnings per share.

What ETF holds CytomX Therapeutics' stock ?

Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio.

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bridgeway Capital Management LLC (0.65%), Assenagon Asset Management S.A. (0.60%), Formidable Asset Management LLC (0.46%), Congress Park Capital LLC (0.36%), Northern Trust Corp (0.20%) and GSA Capital Partners LLP (0.16%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTMX) was last updated on 2/29/2024 by MarketBeat.com Staff